Both in Biotechnology
Lexeo Therapeutics vs SAB Biotherapeutics
Over the past year LXEO returned −65.6% and SABS returned −4.0%; their daily moves had a correlation of 0.25.
LXEO −65.6% SABS −4.0%Growth of $1, one year, split-adjusted
| Metric | LXEO | SABS |
|---|---|---|
| Price | $3.11 | $3.12 |
| Market cap | $255.3M | $283.9M |
| Today | +1.63% | −5.45% |
| 1 month | −8.8% | +0.6% |
| 6 months | −47.8% | −15.2% |
| Year to date | −68.7% | −16.6% |
| 1 year | −68.9% | −4.0% |
| Revenue growth (YoY) | — | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $211.1M | $99.4M |
| Dividend yield | — | — |
| Volatility (60d) | 69.1% | 56.4% |
| Short % of float | 22.9% | 6.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).